Eton Pharmaceutcials financials
$59.19+0.02%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.6M | $24.3M | $21.3M | $22.5M | $18.9M | $17.3M | $11.6M | $10.3M | $9.1M | $8.0M | $7.3M | $7.0M |
| Gross profit | $25.4M | $14.7M | $13.1M | $7.9M | $11.9M | $9.9M | $6.5M | $6.3M | $5.6M | $5.0M | $3.6M | $4.4M |
| Gross margin | 67.6% | 60.7% | 61.6% | 35.0% | 63.0% | 57.1% | 55.6% | 61.0% | 62.0% | 62.9% | 49.6% | 62.6% |
| Operating income | $12.8M | $2.4M | $2.5M | -$1.4M | -$1.5M | -$470.0K | $629.0K | $509.0K | -$2.9M | -$800.0K | -$2.0M | -$548.0K |
| Net income | $11.6M | $1.6M | $1.5M | -$1.9M | -$2.6M | -$1.6M | -$598.0K | $627.0K | -$3.0M | -$811.0K | -$2.3M | -$579.0K |
| Net margin | 30.8% | 6.4% | 7.0% | −8.6% | −13.7% | −9.1% | −5.1% | 6.1% | −33.5% | −10.2% | −30.8% | −8.2% |
| Diluted EPS | $0.35 | $0.05 | $0.06 | $-0.07 | $-0.10 | $-0.06 | $-0.02 | $0.02 | $-0.12 | $-0.03 | $-0.09 | $-0.02 |
| EBITDA | $14.2M | $3.5M | $3.5M | -$354.0K | -$470.0K | $543.0K | $984.0K | $787.0K | -$2.7M | -$566.0K | -$2.0M | -$357.0K |
| Operating cash flow | $7.3M | $7.4M | -$11.6M | $12.0M | $8.0M | $2.1M | -$765.0K | $3.0M | $1.3M | -$2.5M | $387.0K | $873.0K |
| Free cash flow | $7.3M | $7.3M | -$11.6M | $11.7M | $8.0M | $2.1M | -$777.0K | $3.0M | $1.3M | -$2.5M | $387.0K | $873.0K |
| Diluted shares | 32.8M | 31.5M | 27.0M | 26.9M | 26.9M | 26.9M | 25.5M | 26.6M | 25.8M | 25.8M | 25.4M | 25.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.8M | $19.7M | $25.9M | $37.1M | $25.4M | $17.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $27.9M | $30.7M | $30.6M | $30.4M | $30.2M | $30.0M |
| Total assets | $115.8M | $97.7M | $92.1M | $104.5M | $101.7M | $84.0M |
| Total liabilities | $69.2M | $67.1M | $66.0M | $81.4M | $77.7M | $59.6M |
| Shareholders' equity | $46.6M | $30.6M | $26.2M | $23.1M | $24.0M | $24.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology